Previous 10 | Next 10 |
LEXINGTON, Mass. , May 9, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided corporate updates and reported financial results for the first quarter of 2...
LEXINGTON, Mass. , May 3, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , will release its first quarter 2019 financial results before the market op...
Founded by a Nobel prize winner, Bicycle Therapeutics ( BCYC ) has developed a large amount of intangible assets, which should interest investors. Besides, the company reports collaboration agreements with larger pharmaceutical institutions, cash in hand, and no debt. While Bicycle is still at...
Quick Take Bicycle Therapeutics ( BCYC ) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing antibody-like therapeutics for the treatment of underserved diseases. BCYC has developed several commercial c...
LEXINGTON, Mass. , April 2, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , today announced that the first patient was dosed in the clinical trial ...
LEXINGTON, Mass. , March 21, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced new leadership appointments as its CTLA-4 and PD-1 programs advanc...
Agenus Inc. (AGEN) Q4 2018 Results Earnings Conference Call March 14, 2019, 08:30 AM ET Company Participants Jennifer Buell - Chief Operating Officer Garo Armen - Chairman and Chief Executive Officer Anna Wijatyk - Vice President of Clinical Development Christine Klaskin - Vice...
Agenus ( AGEN ) Q4 results : Revenues: $6.5M (-23.5%). More news on: Agenus Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Agenus (NASDAQ: AGEN ): Q4 GAAP EPS of -$0.40 misses by $0.12 . More news on: Agenus Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
LEXINGTON, Mass. , March 14, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and reported financial results for the fourth qu...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...